Reddit Posts
If NDX/M2 Is the Roadmap, is a 25% SPX Correction Next?
Insane low float play last Friday (STAK) — and why I almost missed it
Journaling and Analyzing stocks with a web app certainly makes things easier
Moving Averages Explained: SMA vs EMA, the Golden Cross & the Death Cross (Beginner's In-Depth Guide)
Mentions
Ok SPY, if you reclaim the 9EMA and hold over 734.50, I'll buy calls
Damn, I'm so mad at myself. This should have been an easy day but I didn't follow my own rules. Not one candle closed over the 9 EMA on the 5 min chart, why did I buy calls?? 😭
Pretty crazy thing to do in this market but it happens you need to sit out for a bit and wait until your heads back in the game and start again fresh when the volatility eases. Its below its 200EMA which means its way too risky to even trade let alone do options.
LENZ is LENZ Therapeutics, Inc. (Nasdaq: LENZ), a commercial-stage biotech/pharmaceutical company Key drivers: * **Commercial progress of VIZZ** — Early U.S. sales started modestly (e.g., \~$1.6 million product revenue in Q4 2025 with tens of thousands of prescriptions). Growth in prescriptions, refill rates, eye-care professional uptake, and new channels (including a July 2026 telehealth prescribing option + TV advertising) are closely watched. High operating expenses and cash burn have pressured the stock despite a strong cash position (hundreds of millions, low debt). * **International expansion** — Partnerships and regulatory filings (e.g., Greater China rights via Everest Medicines with potential milestones/royalties, Australia/New Zealand deal, UK MHRA filing, EMA submission). These expand the addressable market but take time to generate revenue. * **Earnings and guidance** — Quarterly results showing revenue vs. expectations and spending levels have caused big moves (often downward on expense concerns). Next earnings were around late July/early August 2026. * **Analyst views and safety/side-effect notes** — Consensus has often been Strong Buy with high price targets (around $32 in some recent aggregates), but targets have been cut as growth assumptions reset. Occasional mentions of adverse events (e.g., retinal tear reports) have also weighed on sentiment.
I am leaning more towards this being the start of a long-term downward trend. There is definitely profit-taking here, and the threat from China is real. The price difference between china models and US models is pretty big, so many AI application builders will really need to start thinking about ditching US frontier models. I would say the biggest impact should be on model companies first (so I'd be worried about Anthropic and OpenAI IPOs), but this effect will begin trickling down to chip designers, manufacturers and their suppliers. Now is not the time to buy the dip in my opinion. Looking at the [techinicals of key semiconductor stocks](https://www.stock-table.com/technicals?public_uuid=6e16b17d-bf31-4fcb-9c15-4110febd5300), i don't see any signs of reversal yet, whether it's EMA, RSI, or MACD. I would shift from growth to value stocks now if you still want to be invested in equities.
Wait what out? Wait to be 280 again? It bounced on 50 week SMA with this earnings, below 200d EMA. It's time to buy.
Lol Kospi, Wild. But that parabolic unwind is close to finished. Might add some KORU soon. 20 month EMA is around 4,900 for Kospi. Should see it turn up for the second attempt at ATH around that level.
Technical analysis is funny because if the stocks fall far enough eventually people run out of things to sell and they call that the “100EMA”
Right on! ORB, sub 1 & 10M, 200-DMA, 8/21 EMA [jkoth2@gmail.com](mailto:jkoth2@gmail.com)
Wow it’s almost like algos are the majority of the volume and they use things like EMA, VWAP, and previous day high low open close to just bounce between. Once you have those levels charted it starts clicking, at least for ES
I have lost my 50 day EMA, has anyone seen it? I looked everywhere, even under the couch cushions.